Sender: Vice-Chancellor Katrin Hamilton
Subject: Planet Carlisle
Transmission Secure
Link Established
Greetings to you
The University of Cambridge wishes to exand a hand of cooperation to Cryer regarding Planet Carlisle in the Newcastle system. As you well know, the planet is well suited for Human habitation save for one thing. The bacteria that calls that planet home, is particularly deadly to Humans. Given the need for suitable worlds in Bretonia, and the loss of Planet Gaia in the Edinburgh system, we ask that we pool our resources into finding a suitable solution to the bacteria problem on Carlisle.
Regards:
Katrin Hamilton
Vice-Chancellor
Univerity of Cambridge.
*Link Lost*
*Transmission Lost*
*END OF TRANSMISSION*
While Cryer Pharmaceuticals isn't necessarily in the terraforming business we are certainly able to lend a hand to squash this bug. I will look into what facility's are available in orbit at the Research Facility. In the meantime I'll need your staffers to send over an estimated budget so we can tailor our response and assign adequate personnel to this project.
Sender: Vice-Chancellor Katrin Hamilton
Subject: Planet Carlisle
Transmission Secure
Link Established
Mister Zambrano
This is hardly a terraforming project, the planet's ecosystem is sound, this is a medical matter. We have sent people to the research station above Cambridge to meet with your own. The Chancellor will contact the Bretonian Government for access to Carlisle soon, if you could choose one or two of your own people to acompany the research teams to the surface (should access be allowed of course) then that would be appreciated.
We do not presume to estimate how much your own work will cost sir. We believe you to be an honest organisation, as such we believe you would be more suited to telling us how much this project will cost. We will see what we can manage, the University's pockets are not endless, we hope you take this into account.
Regards:
Katrin Hamilton
Vice-Chancellor
Univerity of Cambridge.
*Link Lost*
*Transmission Lost*
*END OF TRANSMISSION*
I am Jason Kelly, COO of Cryer Pharmaceuticals and I would like to apologize for taking so long to answer.
However, the fault is entirely on the bacteria from Planet Carlisle, we’ve named “enterohemorrhagic carlisle coli”, ECC for short. You see, ever since the first few casualties of the “Carlisle Disease” we’ve collected tissue-samples for our research, as is standard protocol for new diseases in all colonies. I’m sure the University of Cambridge has a similar standing within Bretonia.
The first idea was to simply eradicate the bacteria using a task-designed bacteriophage to target the bacteria. However, as the bacteria was found to be deeply interwoven into the planet’s ecosystem, a complete eradication of ECC is not an option.
Similarly, antibiotics will not work too, as there will be a continuous intake of ECC, in turn, this means a continuous intake of antibiotics, which will lead to widespread resistance to any antibiotic. So even with the broad range of Antibiotics that Cryer Pharmaceuticals has to offer, this will, at most, be a short-lived solution, we would like to keep as a stop-gap measure, for the following, approved idea:
ECC’s fatality is due to excretion of a verotoxin, that, in layman's terms, dissolves the internal organs. Of course Cryer Pharmaceuticals can nearly immediately synthesize an antidote for any given toxin. However, so far about a dozen strains of ECC have been identified, all with different toxins and due to genetic conjugation the toxins will change over time.
But Cryer Pharmaceuticals has come up with a broad-band inhibitor for all of the found toxins, that gives maximum protection by minimal side-effects. Of course, stage 2 and 3 trials will still have to be conducted, to prove our preliminary findings and stage 3 trials will be an ongoing project as the bacteria is evolving and Cryer Pharmaceuticals will have to constantly monitor and adapt our drug.
However, at that point, we are confident, that we have come up with a product, that is both effective and modifiable to a point, in which we can adapt it quickly enough to any newly formed strain, before the predecessor looses effectiveness.
Sender: Vice-Chancellor Katrin Hamilton
Subject: Planet Carlisle
Transmission Secure
Link Established
Mister Kelly, a pleasure to hear from you. Allow me first to thank you for describing the issue at hand so clearly.
However, before such a vast undertaking can even begin, it might be wise to launch a field expedition to the surface of Carlisle. As dangerous as that sounds, it has been done by our researchers before. Although I am told that the experience was rather traumatic for a few. If we could secure permission however, would you be willing to join a team? Would it be necessary? I must also ask as to what the nature of these 'side effects' that you mentioned are.
If in the event that Cryer was to produce a drug that could allow for permenant settlement, how often would citizens need to undergo vaccination? Once a month? once a week?
Finally, what are your current estimates for cost. The University may be willing to help fund your research, provided that the proctors and the Regents are all in agreement with whatever sum you present to us.
Kind regards:
Katrin Hamilton
Vice-Chancellor
Univerity of Cambridge.
*Link Lost*
*Transmission Lost*
*END OF TRANSMISSION*
We are aware of the horrific fate suffered by the first expedition to Planet Carlisle. We did mention the tissue-samples we received.
Secondly, Cryer Pharmaceuticals has a drug. We were fully aware that development of our broad-band inhibitor was the only thing needed to start colonizing planet Carlisle, as stated in the mission protocol of the first expedition.
Again, as the premier company to develop and produce drugs of any kind, we do enjoy some prerogatives, when it comes to being notified about new diseases.
However, any expedition would need to be classified as stage 2 and lager 3 trial of the drug to prove it’s defectiveness in a non-laboratory environment. These will also yield the answers to your question of side-effects. Once these steps have been completed to our full satisfaction our drug fulfills the requirements to go into the open market.
However, to be honest, our computer models and in-vitro testing have been proven to be extremely accurate, so people prone to hyperacidity, will have to additionally ingest proton-inhibitors and we do not recommend people with renal insufficiency to visit the planet, though this is more of a precaution.
The drug we have designed will have to be taken daily, as this proved the best results in internal testing and will be available in both an oral and an intravenous form, though the later will be restricted to medical professionals , of course, and is intended for emergencies.
As for payment Cryer Pharmaceuticals requires none from the Bretonian Gouverment. In return, we simply ask the Bretonian Government to colonize Carlisle at best speed. However, we will retain all and every right and patents for further development of and to solely produce the drug. We will also set a price, according to our usual policy, and sell the drug on the open market.
It is then up to the Bretonian Government to use it’s prerogative to buy the drug in bulk and distribute it to the inhabitants and visitors of Carlisle, or otherwise subsidize it’s distribution.
As for an expedition, a team of scientists will of course accompany the expedition as part of the medical trials, some of them participating other in bio hazard-suits, again to comply with Bretonian regulations, and rent a room on one of the nearby stations to turn into a temporary quarantine-zone.
As for me, personally, or any of the executives of Cryer Pharmaceuticals, is no need to join, this is a rather standard procedure, although the circumstances might be somewhat out of the extraordinary.
I do hope this answers all of your question. All you need to do is find suitable participants for the expedition willing to participate in stage-2 trials for the first expedition and maybe have the Bretonian Government contact and persuade owners of an orbiting station to provide us with a section of their station to turn into a quarantine-zone.
From your signal on, we can deliver the needed medication for a group up to 20 people within a day or two. And then scale up to 50 to a 100 people for the stage-3 trials, about a month later.
Sender: Vice-Chancellor Katrin Hamilton
Subject: Planet Carlisle
Transmission Secure
Link Established
Mister Kelly
A message was sent to the BPA regarding the use of the facilities on Gateshead. Unfortunatly the BPA declined our request for use, we therefore wish to inquire if the facilities on the Cambridge research station are sufficient for the task at hand.
The University has found several volunteers for both the expedition and for the later trials, should everything go according to plan. Furthermore we shall inform the Bretonian government as to your plans regarding the sale and distribution of this drug once further testing is complete.
Regards:
Katrin Hamilton
Vice-Chancellor
Univerity of Cambridge.
*Link Lost*
*Transmission Lost*
*END OF TRANSMISSION*